Assoc. Prof. Dr. Elif Şenocak Taşçı

Assoc. Prof. Dr. Elif Şenocak Taşçı is a medical oncologist at Acibadem Atakent Hospital in İstanbul, where she works in the Medical Oncology Department. She has more than 20 years in medicine and consults in Turkish and English. Her clinical work centers on the drug-based treatment of solid tumors, including cancers of the breast, lung and chest, digestive tract, urinary tract, female reproductive organs, and head and neck region.

Dr. Taşçı is a graduate of Robert Kolej (2006) and of Yeditepe University Faculty of Medicine (2012). She trained in Internal Medicine at Düzce University Faculty of Medicine, completing this training in 2017, and went on to complete Medical Oncology training at Acıbadem Mehmet Ali Aydınlar University Faculty of Medicine in 2023. Her professional experience includes a position as an Internal Medicine Specialist at Haydarpaşa Numune Training and Research Hospital from 2019 to 2020, a role at Acıbadem Healthcare Services in 2020, and a position as a Medical Oncology Specialist at Kanuni Sultan Süleyman Training and Research Hospital from 2023 to 2025.

Clinical focus

Dr. Taşçı’s areas of expertise cover a range of solid tumors. In gynecologic oncology she treats cervical cancer, endometrial cancer and ovarian cancer. Her gastrointestinal work includes stomach cancer and colorectal cancer, encompassing both colon cancer and rectal cancer. She also manages breast cancer, bladder cancer, lung and thoracic cancers, and head and neck cancers, including nasopharyngeal cancer. As a medical oncologist, her role generally involves assessment of the disease, planning of systemic treatment, and coordination with the other specialists involved in a patient’s care.

Dr. Taşçı has contributed to peer-reviewed research. Her publications include a multi-institutional real-world study comparing total neoadjuvant therapy with neoadjuvant chemoradiation in locally advanced rectal cancer, a multicenter Turkish Oncology Group (TOG) study on adjuvant capecitabine in residual triple-negative breast cancer, a nationwide observational study of first-line nivolumab plus chemotherapy in advanced gastric, gastroesophageal junction and esophageal adenocarcinoma, work on prognostic factors of the perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors, and an observational study on health literacy and HPV knowledge among university students.

How Dr. Taşçı works with international patients

Dr. Taşçı consults in Turkish and English, and interpreters can be arranged for patients who speak other languages. Before a visit, the international patient team coordinates the collection of prior reports and imaging, such as MRI, CT, X-ray or ultrasound reports, laboratory and pathology results, operative notes and discharge summaries, and arranges appointments and the hospital visit. A first consultation typically covers the patient’s history and symptoms, a review of existing imaging and previous treatments, a clinical examination and a discussion of the options. Video consultation is available for international patients.